1.5 mIU/ml Bone age advanced 6 mos'I6 mos therapy. We conclude D-His-A at 4 pglkglday for 3 mos did not decrease growth velocities despite decreases in mean overnight GH. Somatomedin C and gonadalsteroi'ds Mean overnight LH andPSHvalues showed stepwise decrease with higher doses of D-His-A. We suggest that children with D-His-A need a minimum of 8 pg/kg/day and that D-His-A response should be used to evaluate therapy rather than GnRH tests. ACTH insensitivitv is a cardinal feature of ALO. but the mechanism is unknown. we studied a 10 year old hyperpigmented boy with glucocorticoid insufficiency of 8 years duration and a history of two generalized tonic clonic seizures associated with febrile episodes with normal blood glucose. His neurological exam was normal, EEG showed non-specific slowing with normal auditory evoked responses, and Magnetic Resonance Imaging showed areas of increased signal intensity in the cerebral peduncles and the internal capsule. ALD was documented by increased plasma very long chain fatty acids, i.e., C26lC22 = 0.055 (control = 0.01 ' 0.01); C26= 1.572 pglml (control = 0.33 t 0.18 pglml). Basal ACTH was elevated at 1840 pglml (normal = (100 pglml). Cortisol was 7.0 pgldl with no response to exogenous ACTH. Basal and stimulated renin and aldosterone were normal. The child's leukocytes had no detectable ACTH binding sites in a radioligand binding study. In contrast, normal mononuclear leukocytes possess high and low affinity receptors for ACTH that appear identical to the prototype adrenal receptors. These studies suggest that the adrenal failure associated with ALD is secondary to an ACTH receptor defect. Whether the ACTH receptor defect is primary or secondary to the long chain lipid abnormality is under investigation. Growth failure has been observed in children with the acquired immunodeficiency syndrome (AIDS), but the growth pattern in asymptomatic HIV-infection or in AIDS-related complex (ARC) is unknown. We report a 6 10112 year old female with congenital HIV infection and a 2 year history of growth failure. Her father w a s a member of a major risk group and died of AIDS. The child and her mother are HIV antibody-positive by both ELISA and Western blot assays, but neither have had severe infections nor qualify for the diagnosis of AIDS. Based on her declining T4 cell numbers (current absolute T4 cell number = 33/ul), and persistent splenomegaly, this patient is considered to have ARC. Endocrine evaluation: Her peak growth hormone response to arginine was 1.2 nglml and to insulin (glucose = 35 mg/dl) was 2.6 ng/ml; cortisol peak = 27 ugldl with hypoglycemia; TSH = 5.4 uU/ml; T4 = 10.5 ug/dl; IGF-I = 0.2 u/ml; bone age = 5 6/12 yr; sella and suprasellar areas are normal by MRI scan. Her growth velocity and immune function on methionyl human growth hormone are currently being determined. The etiology of this child's growth hormone deficiency is presumed to be secondary to congenital HIV infection with late onset of pituitary or hypothalamic failure. Recognition of this syndrome will undoubtedly become importar in the diagnosis and management of pediatric HIV infection. We tested the hypothesis that GnRH agonist treatment of CPP is associated with loss of bone mineral density (BMD) and content (BMC) after young women treated with GnRH agonists were reported to lose up to 6% BMD in the first treatment year similar to that seen during menopause. W e determined lumbar spine (Ll-L4) BMD (g/cm2) and BMC (g) by dual photon absorptiometry and measured growth parameters and blood Ca (mg/dl), alk. phos. (AP,mU/ml) and integrated growth hormone (GH, ng/ml) on CPP patients before and after (3 of our 6 patients to date) six months treatment with the GnRH agonist LUPRON (TAP Pharm., 4-8 ug/kg SC qD). Our patients (3 girls 5-8 yr, 9-10 yr bone age [BAI; 3 boys 3-8 yr, 7-10 yr BA) were Stage 3-4 upon entering the study with informed consent.
ISOLATED GROWTH HORMONE DEFICIENCY IN ASSOCIATION WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION
Before Previous studies have shown that gonadotropin response to I/V bolus injection of GnRH differs in prepubertal (PPP) and pubertal patients (PP). In the PPP patients GnRH response is minimal, with the LH/FSH ratio being less than one. In contrast, the PP patient demonstrates a marked response in LH secretion with the LH/FSH ratio being greater than one.
We studied a group of 12 girls, aged 6 to 8 years, designated as Aborted Puberty (AB). They all presented with signs of precocious puberty (breast & pubic hair development) but differed from true precocious puberty in that their early pubertal development spontaneously regressed. These AB patients responded differently to GnRH than expected, as seen in the table below. To investigate the pathophysiology of hypothalamic-pituitary-adrenal axis in patients (pt) with a mild defect in adrenal steroidogenesis, ACPH and adrenal steroid response (180 min) to ovine CRF (1 ug/kg IV bolus at 1600 hr) in 3 pt with late diagnosis of 1W-hydroxylase (116-0~) deficiency (def) and in 7 pt with late-onset 21-hydroxylase def (21-OH) or 36-01 dehydroge nase def (38-HS)) here conpred with the responses in 8 oontrols. In all pt, levels of adrenal precursor steroids proxirnal to the particular enzyme block wre high following CRF. Basal and CRFstimlated ACI'H & F levels were norrnal irrespective of enzyne def or mgnitude of the rise of the precursor steroid in all pt but 2 (11B-OH def) in whom ACPH response to CRF was high ard F respnse low, with lower precursor steroid response than in the pt with n o m l ACPH and F. Conclusion: In pt with defects in adrenal steroidogenesis, mnpensatory ACI'H hypersecretion occurs only when F secretion is inadequate. Normal ACPH secretion is seen in pt with n o d F secretion despite increased precursor steroids.
Mechanism for normal F without excess ACPH remains to be defined.
